Table I. Patient Characteristics.
| Total (N = 53) | |
|---|---|
| Age, median (range) | 64 (37–82) |
| Age> 65 years | 23 (43%) |
| Gender, male | 27 (51%) |
| ECOG Performance Score | |
| 0 | 21 (40%) |
| 1 | 24 (45%) |
| 2 | 8 (15%) |
| ISS Stage | |
| Stage I | 18 (34%) |
| Stage II | 21 (40%) |
| Stage III | 14 (26%) |
| Isotype | |
| IgG | 36 (68%) |
| IgA | 10 (19%) |
| Light-chain | 9 (17%) |
| Parameters of Hematologic Response | |
| Serum M-Spike ≥ 1.0 g/dL | 39 (74%) |
| Serum Free Light Chain ≥ 10 mg/dL | 35 (66%) |
| Urine M-Spike ≥ 200 mg/24 hr | 15 (28%) |
| Bone Marrow Plasma Cells > 30% | 31 (58%) |
| High-risk Multiple Myeloma | 14 (26%) |
| t(4;14) | 4 (8%) |
| t(14;16) | 2 (4%) |
| Del 17p- | 4 (8%) |
| Del 13 (metaphase cytogenetics) | 3 (6%) |
| PCLI > 3% | 7 (13%) |
| Serum Creatinine, mg/dL; median (range) | 1.0 (0.6–2.1) |
| Creatinine clearance < 50 mL/mina | 8 (15%) |
| Lytic bone disease | 40 (75%) |
a
Calculated creatinine clearance.
N (%) unless otherwise indicated.